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A b s t r a c t  
For locally acting intranasal drugs, an extended residence time in the nasal cavity is desirable and 
related to a prolonged effect. The aim of the present work was to design a nasal delivery system 
with improved mucoadhesive properties that could provide prolonged retention time for the 
treatment of allergic rhinitis. A 32 factorial design was used to investigate effect of amount of gellan 
gum and mucoadhesive polymer namely HPMC E4M as independent variable. Viscosity and 
mucoadhesive strength were taken as dependent variables. The formulations were tested for 
gelation study, viscosity study, gel strength, mucoadhesion study, shot weight study, drug content, 
histopathological evaluation, and stability study. Gelation was determined by physical appearance. 
Viscosity study of sol and gel formulations indicated that increase in polymer concentration 
increases the viscosity. Shot weight of the formulations was found to proportionally vary with the 
viscosity of formulations. Gel strength was found in the range of 22-55 sec. The mucoadhesive force 
in terms of detachment stress increased with increase in the concentration of HPMCE4M. 
Histopathological examination of sheep nasal mucosa with control and optimized formulation did not 
show any change in the nasal tissue. A stability study for optimized AZ5 formulation as per ICH 
guideline for 90 days showed no change in pH, drug content, and viscosity. The developed in situ 
gelling system for azelastine hydrochloride using gellan gum in combination with HPMC E4M with 
improved mucoadhesive properties that could provide prolonged retention time for the treatment of 
allergic rhinitis. 
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Introduction 
The nasal route is an important mode of drug delivery, with a 
growing number of products available for administration through 
this route for systemic and local action, such as for allergic rhinitis. 
For locally acting anti-allergic drugs, an extended residence time in 
the nasal tissue is related to a prolonged pharmacologic activity. 
An additional advantage is the slow distribution into systemic 
circulation resulting in low plasma concentrations and therefore a 
low risk of systemic toxicity [1]. One of the constraints of delivering 
drugs via the nose is the capacity of the nasal cavity; the maximum 
volume administered is typically only about 0.2 ml per nostril. Even 
at these low volumes, delivery of many nasal products, typically 
simple aqueous solutions, is sub-optimal, notably when post nasal 
drip or run-off into the throat gives rise to discomfort/tolerability 
issues or reduced/variable absorption and therefore efficacy. Gel 
formulations have the potential to reduce mucociliary clearance, 
post-nasal drip and anterior leakage. But the effective delivery of a 
nasal product formulated as a gel is technically challenging, 
especially ensuring effective deposition and distribution within the 
nasal cavity [2]. It is well known that the  allergic rhinitis is an 
inflammatory disease of the upper airway, which is accompanied 
by sneezing, itching, congestion, rhinorrhea and loss of the sense 
of smell. These symptoms are considered to be caused by 
antigenăantibody reaction on mast cells that are located on the 
epithelia of the nasal cavity [3]. Azelastine hydrochloride is an 
intranasal antihistamine indicated for use in patients with seasonal 
allergic rhinitis and non-allergic vasomotor rhinitis [4]. In situ gel is 
a new dosage form which has been applied in nasal drug delivery 
recently. Compared with liquid nasal formulations, nasal in situ gels 
are instilled as low viscosity solutions into the nasal cavity. Upon 
contact with the nasal mucosa, the polymer changes conformation 
producing a gel, so that it can not only prolong the contact time 
between the drug and the absorptive sites in the nasal cavity, but 
also releases drug slowly and continuously. Hence, it is especially 
useful for those drugs used chronically. Gellan gum is an anionic 
deacetylated, exocellular polysaccharide secreted by 
Pseudomonas elodea. The mechanism of gelation involves the 
formation of double-helical junction zones followed by aggregation 
of the double-helical segments to form a 3-D network by 
complexation with cations and hydrogen bonding with water [5].  
Since human nasal mucosa is covered with approximately 0.1 ml 
mucus, which consists of sodium, potassium, and calcium ions, a 
solution-gel phase transition can be expected. Till date, there is no 
report on preparation of in situ nasal gel of azelastine 
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hydrochloride. The objective of the present work was to design a 
nasal delivery system for azelastine hydrochloride based upon the 
concept of ion activated in situ gelation with improved 
mucoadhesive properties that could provide prolonged retention 
time for the treatment of allergic rhinitis. 
Materials 
Azelastine Hydrochloride was a gift sample from MSN 
Laboratories, India. Gellan gum were procured as gift samples 
from CPKelco Signet Chemical Corporation Ltd. HPMC E4M was a 
gift sample from Colorcon, Mumbai, India. Nasal device procured 
as a gift sample from Vinis Products Pvt. Ltd, Mumbai, India. 
Mannitol and Benzalkonium chloride were obtained from 
Wockhardt Ltd, Aurangabad. All other chemicals were of analytical 
reagent grade. 
Methods 
Preparation of in situ gels 
Gellan gum was weighed and dispersed in ultra-pure water. The 
dispersions were then stirred by mechanical stirrer (Remi motors 
ltd, Mumbai, India, type RQ-122) for 30 min at 90ĈC in a water bath 
and then cooled to room temperature. HPMC E4M was weighed 
and dissolved in ultra-pure water and heated at 900C then cooled 
to room temperature. 10 ml of chilled water was added to   it. 
Azelastine hydrochloride (AZ HCL) (0.1% w/v) was added in small 
volume of ultra-pure water and sonicated (Toshcon ultrasonic 
cleaner, Toshniwal instrument Pvt. Ltd. Ajmer) for 30min. 
HPMCE4M solution and drug solution were added in gellan gum 
solution slowly with continuous stirring. Appropriate quantities of 
mannitol and benzalkonium chloride (BKC) were added 
simultaneously. The formulations were filled in bottles. The 
formulation layout for the factorial design batches (AZ1 to AZ9) are 
shown in Table 1. 
Table 1: Composition of all nasal in situ gel formulation 
Sr no Ingredients AZ1 AZ2 AZ3 AZ4 AZ5 AZ6 AZ7 AZ8 AZ9 
1 AZ HCL 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
2 Gellan gum 0.3 0.3 0.3 0.4 0.4 0.4 0.5 0.5 0.5 
3 HPMC E4M 0.05 0.1 0.15 0.05 0.1 0.15 0.05 0.1 0.15
4 Mannitol 4 4 4 4 4 4 4 4 4
5 BKC 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
6 Purified water quantity sufficient. 100ml 100ml 100ml 100ml 100ml 100ml 100ml 100ml 100ml 
                         
Experimental design 
A 32 randomized full factorial design was used in the present study 
(Design Expert 8.0.7.1). Two independent factors were evaluated, 
each at 3 levels, and experimental trials were performed for all 9 
possible combinations. The concentration of gellan gum (X1) and 
concentration of HPMC E4M (X2) were chosen as independent 
variables. Viscosity and mucoadhesive strength were taken as 
dependent variables.  
Evaluation of prepared in situ gels 
Appearance 
The developed formulations were inspected visually for clarity in 
sol and gel form. 
Gelation study 
The Simulated Nasal Fluid, SNF (aqueous solution containing 8.77 
mg/ml NaCl, 2.98 mg/ml KCl and 0.59 mg/ml CaCl2 per liter), 
having the cationic composition of nasal secretions, was prepared 
according to the report. Gellan gum is a polymer which undergoes 
change from sol to gel in the presence of cations. Gelation is the 
process by which the liquid phase (sol) makes a transition into gel. 
Azelastine hydrochloride in situ gel and simulated nasal fluid were 
mixed in 1:1v/v ratio. The gelation study was done on magnetic 
stirrer (1MLH magnetic stirrer, Remi). The gelation point was 
determined when the magnetic bar stopped moving due to 
gelation. The consistency of formed gel was checked and graded, 
as indicated in Table 2. 
Viscosity and rheological study 
The viscosity of nasal in situ gel formulation before and after 
gelation was determined using Brookfield Rheometer R/S-CPS 
+1600, Lauda Ecoline Staredition RE-204, having cone-and-plate 
geometry by using spindle coaxial CP75-1. The shear rate was 
varied from 1 to 1000/s. Samples were applied to the plate using a 
spatula(approximately 2 ml) to ensure that formulation shearing did 
not occur. Each point is the average of at least three readings [6]. 
pH study 
pH of all formulations was determined by using pH meter (Model 
No. EQ-621, Equip Tronix microcontroller pH meter). 
Gel strength study 
The gel strength is an indication of the viscosity of the nasal in situ 
gel at physiological condition. It is expressed in terms of seconds 
required by a 35 g piston for penetration of 5 cm distance, through 
the 50 g gel formulation. This test was performed using ÂGel 
strength apparatusÊ modified at the laboratory [7]. In situ gel 
formulation (50 g) was placed in a 100 ml-measuring cylinder and 
gelation was induced by SNF. The apparatus for measuring gel 
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strength (weight: 35 g) was then placed on the gel. In case the 
apparatus  took more than 10 min to drop into the gel, various 
weights were placed on top of the apparatus. The gel strength was 
measured by the minimal weight that pushed the apparatus 5 cm 
down through the gel [8]. 
Mucoadhesive strength study 
Mucoadhesive Strengths of gel was determined by the method 
reported [9,10]. Nasal mucosal tissue, obtained from the local 
slaughterhouse (Aurangabad), was carefully removed from the 
nasal cavity of sheep and mounted on glass surface using 
adhesive tape while another mucosal section was fixed in inverted 
position to the cylinder. 50mg of gel was placed on mucosal 
surface. The glass mounted mucosal surface with gel formulation 
and mucosal surface attached to cylinder were held in contact with 
each other for 2min to ensure intimate contact between them. In 
second pan, the weights were increased until the two mucosal 
tissues got detached from each other. The nasal mucosa was 
changed for each measurement.  
The mucoadhesive force expressed as the detachment stress in 
dynes/cm2was determined from the minimal weight that detached 
the mucosal tissue from surface of each formulation.  
Mucoadhesive Strength (dynes/cm 2) = mg/A (1)  
Where, m = weight required for detachment in gram,  
g = Acceleration due to gravity (980cm/s2),  
A = Area of mucosa exposed. 
Shot weight study 
Shot weight study was performed to assess pump-pump 
reproducibility and to evaluate the delivery from the pump (137 øl, 
PP Bottles). Shot weights were assessed by weighing the spray 
pumps prior to and after each actuation using an analytical balance 
(A and D Company, Ltd, Japan) having maximum weighing 
capacity of 210 gm with readability to 0.1 mg. In general, pump 
spray weight delivery acceptance criteria should control the weight 
of the individual spray within 15% of the target weight and the 
mean weight within 10% of the target weight [11]. 
Drug content 
1 ml of formulation was taken in 10 ml volumetric flask, diluted to 
10 ml with phosphate buffer pH 6.6 and shaken to dissolve the 
drug. The content of the drug was estimated on UV-Visible 
Spectrophotometer (Shimadzu, UV-1700, LabIndia) at λmax 
212.20nm. 
Histopathological study 
Nasal mucosal tissue incubated in phosphate buffer (control) after 
collection was compared with tissue incubated with in situ gel 
formulation (AZ5). Tissue was fixed in 10% buffered formalin (pH 
7.2), routinely processed and embedded in paraffin. Paraffin 
sections (7 μm) were cut on glass slides and stained with 
hematoxylin and eosin (HE). Sections were examined under a light 
microscope to detect any change in the tissue. 
Drug-excipients interaction study 
Differential Scanning Calorimeter DSC-60 (Shimadzu, Japan.DSC-
60) was used to study the interaction between the drug and 
excipients. Samples, 5.4mg, were weighed and sealed in standard 
aluminum pan and then scanned over a temperature range from 
1500C to 3000C at a heating rate of 20.000C / min. 
Stability studies 
The stability of optimized formulation AZ5 was tested according to 
ICH guideline, at 400Cμ20C/ 75%RHμ 5% condition in stability 
camber (HMG, India) for three months [12]. Tablets were tested for 
drug content for 30, 60, and 90 days. 
Result and Discussion 
Gellan gum, forms gel in presence of cations. HPMC E4M, a 
mucoadhesive polymer, was added to improve mucoadhesion. 
Mannitol was used for adjusting tonicity and benzalkonium chloride 
as preservative. 
Appearance 
All formulations were found clear in both sol and gel form. 
Gelation study 
In vitro gel study was carried out by using simulated nasal fluid. 
Gelation was assessed on a scale ranging between ă and +++, as 
shown in Table 2. The composition of nasal electrolyte was rich in 
cationic content. After instillation into the nasal cavity the liquid 
solution should undergo a rapid change from sol-to-gel transition 
by means of ionic gelation. All gellan gum formulations showed 
instantaneous gelation, depending upon the polymer concentration. 
Formulation AZ1 showed less gelation as compared to AZ9. This 
indicates that with an increase in concentration of gellan gum, the 
gelation point increases (immediate gelation). From the gelation 
study, it was observed that the HPMC E4M did not affect the 
gelation property but the gellan gum plays a critical role in hydrogel 
formation. 
Viscosity and rheological study 
The main requirement of in situ gelling system for nasal 
administration is optimum viscosity that will allow easy spray as a 
liquid from nasal device, which then undergoes a rapid sol-gel 
transition due to ionic interaction. In addition, the formed gel should 
preserve its integrity to facilitate sustained release of drug locally 
for prolonged period without dissolving or eroding quickly. For 
satisfactory gel strength the selection of the concentration of gellan 
gum for use as a delivery vehicle and an acceptable viscosity for 
ease of spraying from the nasal device. Viscosity of all formulations 
containing liquid and gel was studied using Brookfield viscometer. 
The increase in viscosity of all formulations was observed after sol-
to-gel transition. A large change in viscosity of formulations was 
observed with gelling polymer, gellan gum, compared to HPMC 
E4M. The viscosity of both, solution and gel formulations, was 
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found to be proportionate to the increase in polymer concentration. 
All the formulations in solution state showed  Newtonian flow 
whereas gels exhibited non-Newtonian flow as shown in Figure. 1.  
 
 
Figure 1 Showing Newtonian flow for sol and non-Newtonian flow for gel. 
 
Table 2: pH, Drug content, Gelation capacity, Viscosity, Gel strength , Shot weight studies and Mucoadhesive strength  of all formulation  
Batch 
code pH* 
Drug 
content* 
Gelling 
capacity Viscosity (cps) 
Gel 
strength(sec)* 
Shot weight 
(mg) 
Mucoadhesive 
strength(dynes/cm2)*  
        Solution* Gel       
AZ1 6.53μ0.05 98.48μ0.3 ++ 28.16μ2.14 98.6 22.33μ1.15 136.974 2044.37 
AZ2 6.54μ0.02 98.92μ0.2 ++ 34.17μ2.34 115.12 26.67μ1.53 136.960 2395.11 
AZ3 6.54μ0.08 98.96μ0.1 ++ 43.41μ1.04 130.19 31.00μ1.00 136.951 2709.97 
AZ4 6.56μ0.06 98.62μ0.0 +++ 50.15μ3.06 150.11 32.33μ0.58 136.945 2159.65 
AZ5 6.58μ0.05 98.18μ0.3 +++ 55.55μ0.99 166.25 35.67μ0.58 136.938 2504.66 
AZ6 6.60μ0.05 98.04μ0.8 +++ 67.85μ2.83 180.94 37.33μ0.58 136.934 2858.80 
AZ7 6.62μ0.01 97.82μ0.1 +++ 79.46μ1.36 205.94 42.33μ1.15 136.925 2390.22 
AZ8 6.64μ0.06 98.15μ0.1 +++ 96.31μ2.04 222.14 46.33μ1.53 136.914 2711.45 
AZ9 6.65μ0.03 98.29μ0.1 +++ 103.03μ2.1 243.84 52.33μ1.53 136.911 3030.14
(+ +) Immediate gelation remains for few hours (less stiff gel) (+ + +) Immediate gelation remains for extended period (stiff gel).*denotes all values with standard 
deviation (S.D), n=3 
 
pH study 
The normal physiological pH of nasal mucosa is 4.5 ă 6.5. 
However, the nasal mucosa can tolerate solutions within pH range 
of 3-10. The pH of all formulations was found to be in the range of 
6.53-6.65 as shown in Table 2. 
Gel strength 
In the development of a nasal in situ gelling system, the gel 
strength is an important criteria, which allows easy administration 
as droplets and extends the post-nasal drip of the nasal 
formulation. The gel strength values between 25ă50 sec are 
considered adequate. The gel strength less than 25 sec may not 
retain its integrity and may erode rapidly while gel having strength 
greater than 50 sec is too stiff and may cause discomfort to the 
mucosal surfaces. All the formulations had gel strength between 
22.33 sec to 52.33 sec in triplicate as shown in Table. 2  and were 
considered suitable for nasal administration.  
Mucoadhesive strength study 
Mucoadhesive strength was determined in terms of detachment 
stress.  All formulations were subjected to in vitro mucoadhesion 
strength test. Our study indicates that the variation in concentration 
of HPMC E4M and gellan gum changes mucoadhesive strength. 
Figure 2 shows the effect of gellan gum and HPMC E4M on 
mucoadhesion strength. The significant effect was observed with 
HPMC E4M as compared to gellan gum. This was due to wetting 
and swelling of HPMC, which permits intimate contact with nasal 
tissue, interpenetration of mucoadhesive HPMC chains with mucin 
molecules leading to entanglement and formation of weak chemical 
bonds between entangled chains. Due to stronger mucoadhesive 
force, it can prevent the gelled solution coming out of the nose and 
increases its residence time in nasal cavity. But higher ratio of 
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HPMC, responsible for excessive mucoadhesive force, and gellan 
gum can damage the nasal mucosal membrane. Mucoadhesion 
strength of all formulations is shown in Table 2. 
 
 
Figure 2  Displays the effects of gellan gum and HPMC E4M on mucoadhesion force. 
 
Shot weight study 
The delivery of formulation from nasal device mostly depends on 
the device chemistry and viscosity of the formulation. To assess 
device-device reproducibility, it is essential to carry out shot weight 
study. The study was done on all formulations, and it was found 
that as the viscosity of the formulation increases, the weight of 
formulation after the actuation decreases. Table 2 shows the shot 
weight of all nasal in situ gel formulation. 
Drug content 
The percent drug content of all formulations was found to be in the 
range, 97.82-98.92%, which is within the acceptable limit. The 
results are shown in Table.2.  
Histopathological study 
The histopathological study showed no significant effect of the 
optimized formulation on the microscopic structure of the mucosa. 
As shown in Figure 3. The epithelium layer was intact and there 
were no alterations in basal membrane and superficial part of 
submucosa as compared with phosphate buffer treated mucosa 
(control). Thus, the formulation seems to be safe for nasal 
administration. 
 
Figure 3 Histopathological examination of nasal mucosa. 
 
Drug-excipients interaction study 
Differential scanning calorimetric determination revealed that, the 
endothermic peak of pure drug starts from 218.750C and ends at 
236.470C, where as endothermic peak of the formulation starts 
from 214.430C and ends at 231.250C. Azelastine hydrochloride 
exhibited a sharp endothermic peak at 228ĈC while formulation 
showed an endothermic peak at around 225ĈC. This indicates no 
interaction between drug and excipients. The findings are shown in 
Figure 4. 
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Figure  4 Showing DSC of drug and formulation. 
 
Validation of the Experimental Design 
In order to validate the experimental design using a polynomial 
equation, three parameters namely viscosity and mucoadhesive 
strength were selected. The following second order polynomial 
equation was applied as a tool of mathematical modeling: 
 
                      Y= b0+b1 X1+b2 X2+b12 X1X2+b11X12+b22X22 
 
Where, Y is the dependent variable, b0 is the arithmetic mean 
response of the nine runs and b1 (b1,b2,,b12,b11 and b22) is the 
estimated coefficient for corresponding factor X1 
(X1,X2,X12,X11,and X22), which represents the average results of 
changing one factor at a time from its low to high value. The term 
X12 and X22 indicate curvilinear relationship. The interaction term 
(X1X2) depicts the changes in the response when two factors are 
simultaneously changed.  
The parameter viscosity can be described by the model equation, 
                Y (viscosity) =+62.01+28.84X1+9.42X2 
The positive sign for coefficient X1 and X2 indicates that as 
concentration of gellan gum and HPMC E4M increases, viscosity 
increases. R2 value 0.978 for viscosity indicating good correlation 
between independent and dependent variable. The term with 
(P<0.0001) were considered significant. 
The parameter mucoadhesive strength can be described by model 
equation, 
        Y(mucoadhesivestrength) =+2533.81+163.729X1+334.110X2 
 
The positive sign for coefficient X1 and X2 indicates that as 
concentration of gellan gum and HPMC E4M increases 
mucoadhesive strength increases.R2 value 0.995 for 
mucoadhesive strength indicating good correlation between 
independent and dependent variable. The term with (P<0.0001) 
were considered significant. 
The computer generated response surface for dependent variables 
are shown in Figure 5. 
 
Figure 5 Surface response plot for A) viscosity, B) mucoadhesive strength. 
 
Stability study  
Stability study provide a means for checking the physical and 
chemical stability of the drug product at various storage conditions, 
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including the compatibility of the formulation with the components 
of the device, as well as performance of nasal and inhalation spray 
drug products. The physical instability could be due to interaction of 
drug with the excipient used in the formulation. The degradation of 
drug may occur due to its inherent instability or due to its 
interaction with excipient used in the formulation. Formulation 
batch AZ5 was placed for stability study. There were no significant 
changes in visual appearance, pH, drug content and viscosity of 
the formulation was found (Table 3).  
 
Table 3: Stability data of optimized batch AZ5 
Sr no. Test Time interval (month) Initial 400C/75%RH 
1 Appearance 3 Clear clear 
2 pH 
1
6.58μ0.05 
6.58 
2 6.59 
3 6.58 
3 % Drug Content 
1
98.18μ0.32 
98.14 
2 98.1 
3 97.98 
4 Viscosity(cps) 
1
55.55μ0.99 
53.48 
2 54.68 
3 56.12 
 
Conclusion 
In the present study, gellan gum with HPMC E4M was used for the 
nasal drug delivery system of the antihistaminic drug azelastine 
hydrochloride. Owing to its increased viscosity after gelation and 
mucoadhesive characteristics, the formulation displays prolonged 
nasal residence time. Among all formulations, AZ5, containing 
0.4% gellan gum and 0.1% HPMC E4M, was found to be optimized 
formulation. It can be concluded that the optimized in situ nasal gel 
of azelastine hydrochloride appears to be suitable in seasonal 
allergic rhinitis, with prolonged residence time. 
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